Granite Point Capital is a hedge fund. They have closed-end investment office in Boston, MA. Jeffrey Barnett, the chief operating officer
Business Model:
Revenue: $27.2M
Employees: 51-200
Address: 222 Berkeley St
City: Boston
State: MA
Zip: 02116
Country: US
Granite Point Capital is a hedge fund. They have closed-end investment office in Boston, MA. Jeffrey Barnett, the chief operating officer of Granite Point Capital in Boston, is responsible for all aspects of the firm&s;s business, including human resources, systems, trading, compliance and risk management. He also serves on the firm&s;s investment committee, and has been instrumental in crafting a number of its investments in private equity transactions. Launched in February of 2004, Granite Point Capital is a research-driven, long/short equity hedge fund with a global mandate and a focus on mid-small cap US equities. Although primarily focused on the public markets, it has invested in a number of PIPEs, private equity and venture-backed companies.
Contact Phone:
+16175877507
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2018 | Teikametrics | Series A | 10M |
6/2018 | Cerebral Therapeutics | Series A | 3M |
1/2020 | Cerebral Therapeutics | Series B | 35M |
2/2020 | Teikametrics | Equity | 15M |
7/2021 | Teikametrics | Series B | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
5/2016 | Cyber adAPT | Series A | 0 |
4/2021 | Antios Therapeutics | Series B | 0 |
10/2009 | Health Guru Media Inc. | Series C | 3.2M |
3/2019 | Cerebral Therapeutics | Series A | 7.8M |
4/2022 | Receptor Life Sciences | Series A | 9.7M |
6/2022 | Cerebral Therapeutics | Series C | 40M |
9/2017 | Engage Therapeutics | Series A | 23.6M |
6/2022 | Cerebral Therapeutics | Series C | 0 |
4/2022 | Receptor Life Sciences | Series A | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
7/2021 | Teikametrics | Series B | 0 |
4/2021 | Antios Therapeutics | Series B | 0 |
2/2020 | Teikametrics | Venture Round | 0 |
1/2020 | Cerebral Therapeutics | Series B | 0 |
3/2019 | Cerebral Therapeutics | Series A | 0 |
10/2018 | Teikametrics | Series A | 0 |
6/2018 | Cerebral Therapeutics | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|